GlassScriptPhysician profile
Lisheng Kong
NPI 1891764775
$13,810.55
in general payments reported to CMS, 2019-2025
29 companies · $5,149 in 2025
The $5,149 reported for 2025 was more than what 84% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $192 · 2021: $2,621 · 2022: $988 · 2023: $2,439 · 2024: $1,562 · 2025: $5,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,400 · Long Term Medical Supply Or Device Loan: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.57 |
| Long Term Medical Supply Or Device Loan | $3,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,750.00 | 2025 | Auryon Laser System 100-120 Vac |
| Medtronic, INC. | $3,475.33 | 2021-2025 | Concertotm, Hawkone, Venaseal |
| Philips North America LLC | $1,419.46 | 2022-2025 | Phoenix, (Dd1) Duo Hybrid, (9281) Turbo Elite |
| Imperative Care, INC | $991.55 | 2023-2025 | Prodigy Catheter, Symphony Catheter |
| Endologix LLC | $613.69 | 2019-2022 | |
| Inari Medical, INC. | $600.38 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $436.99 | 2019-2025 | Wavewriter Alpha Prime 16, Vigilant X4 Crt-D, Lux-Dx Insertable Cardiac Monitor |
| Reflow Medical INC | $426.87 | 2024-2025 | |
| W. L. Gore & Associates, INC. | $363.89 | 2019-2024 | Gore Viabahn Vbx Balloon Expandable Endo, Excluder Conformable Aaa Endoprosthesis With Active Control |
| Janssen Pharmaceuticals, INC | $279.19 | 2019-2023 | Xarelto |
| Silk Road Medical, INC. | $246.97 | 2021-2022 | |
| Medtronic Vascular, INC. | $233.36 | 2019-2020 | |
| Bolton Medical INC | $130.36 | 2023 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Kerecis Limited | $126.79 | 2021 | |
| Penumbra, INC. | $118.30 | 2025 | Indigo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.34 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $91.92 | 2021 | |
| Smith+Nephew, INC. | $75.98 | 2021-2025 | Collagenase Santyl |
| Vertex Pharmaceuticals Incorporated | $71.63 | 2025 | |
| Cardiovascular Systems INC. | $47.81 | 2021 | |
| Lemaitre Vascular, INC. | $32.95 | 2022-2023 | Artegraft Vascular Graft |
| Abbott Laboratories | $24.78 | 2021 | |
| Fresenius USA Marketing, INC. | $23.85 | 2025 | Velphoro |
| Pacira Pharmaceuticals Incorporated | $21.20 | 2025 | Exparel |
| Cagent Vascular INC | $21.00 | 2025 | Serrantor |
| Inspiremd LTD | $20.61 | 2025 | Cguard Prime Carotid Stent System |
| Getinge USA Sales, LLC | $18.32 | 2020 | |
| Bard Peripheral Vascular, INC. | $16.28 | 2021 | |
| Tactile Systems Technology INC | $15.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisheng Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.